AXA Wins Eight Accolades at The Hong Kong Insurance Awards 2026

HONG KONG, Oct. 30, 2026 /PRNewswire/ -- AXA Hong Kong and Macau ("AXA") received eight accolades at The Hong Kong Insurance Awards 2026, comprising 3 Winner of the Year awards and 5 Top 3 awards, making it one of the most awarded insurers of the year. The awards span a broad range of categories across AI and advanced analytics, financial consultant excellence, product and service innovation, customer service, ESG and sustainability, employee benefits and integrated marketing. These achievements underscore AXA's commitment to innovation and service excellence, and to creating long-term value for customers, business partners and the wider community.

The awards received include:

Winner of the Year:
AI & Advanced Analytics Excellence Award
Most Innovative Product/Services Award (General Insurance) - "Satisfaction Guarantee" Protection
Outstanding Integrated Marketing Excellence Award (Life Insurance) - Fear No Challenge, Protect What Matters

Top 3:
Excellence in ESG and Sustainability Award
Outstanding MPF/Employees' Benefit Product/Service Award
Outstanding Customer Services Award (General Insurance)
Outstanding Agent of the Year – Jan Ng (Finstyle J Agency)
Outstanding Young Professional of the Year – Intermediary – Janice Cheung (ACME Stanley Cheung Agency)

Sally Wan, Chief Executive Officer, AXA Greater China and AXA Global Private, said, "We are honoured to receive these awards, which reflect the dedication of our colleagues and financial consultants and the breadth of excellence across our business. From AI and product innovation to customer service, financial consultant excellence, sustainability, employee benefits and integrated marketing, these recognitions affirm our commitment to continuous innovation and delivering meaningful value for our customers and communities. We will continue to build on this momentum to elevate customer experience and strengthen our capabilities to meet customers' evolving needs."

Organised by The Hong Kong Federation of Insurers, The Hong Kong Insurance Awards celebrate outstanding achievements and innovation across Hong Kong's insurance sector. Since their inception in 2014, the awards have recognised insurers and industry professionals for their forward-looking initiatives, innovative solutions, commitment to customer excellence, and contributions to the sustainable development of the industry.

About AXA Hong Kong and Macau

AXA Hong Kong and Macau is a member of the AXA Group, a leading global insurer with presence in 52 markets and serving 92 million customers worldwide. Our purpose is to act for human progress by protecting what matters.

As one of the most diversified insurers in Hong Kong, we offer integrated solutions across Life, Health and General Insurance. We are the largest General Insurance provider and a major Health and Employee Benefits provider. Our aim is to not only be the insurer to provide comprehensive protection to our customers, but also a holistic partner to the individuals, businesses and community we serve. At the core of our service commitment is continuous product & service innovation and customer experience enrichment, which is achieved through actively listening to our customers' needs and leveraging and investing in technology and digital transformation.

We embrace our responsibility to be a driving force against climate change and a force for good to create shared value for our community. Our overall Sustainability Strategy, with emphasis on nature protection, inclusive protection and social resilience, provides a foundation for integrating environmental, social and governance considerations across our business. We are proud to be the first insurer to address the importance of mental health through different products and services and thought leading iconic research. Committed to shaping a sustainable future, we contribute in diverse ways through three distinct roles - as an investor, an insurer and an exemplary company.

THIS PRESS RELEASE IS AVAILABLE ON AXA'S WEBSITE: AXA.COM.HK 

IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause AXA's actual results to differ materially from those expressed or implied in the forward-looking statements. Please refer to Part 4 - "Risk factors and risk management" of AXA's Universal Registration Document for the year ended December 31, 2019, for a description of certain important factors, risks and uncertainties that may affect AXA's business, and/or results of operations. AXA undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as part of applicable regulatory or legal obligations.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

AXA Wins Eight Accolades at The Hong Kong Insurance Awards 2026

BOSTON, , Oct. 31, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President of Medicilon, and their team welcomed them. The two parties held in-depth discussions on project progress, data transfer, and strategic priorities for the coming year. During the visit, Medicilon presented Revolution Medicines with the "Excellence in Client Partnership Award," recognizing the substantial clinical value of the company's pioneering pan-KRAS drug discovery and development. The award also honors years of joint effort, mutual trust, and shared success by both R&D teams, setting an outstanding example of bilateral collaboration.

A Three-Year Partnership Built on a Trusted R&D Model

Over the past three years, Medicilon's FTE team has worked closely with Revolution Medicines to tackle R&D technical challenges, consistently prioritizing client needs and focusing on the single objective of efficiently delivering high-quality molecules. This partnership has established a model of mutual trust and robust CRO–client collaboration.

At the award ceremony, Dr. Duan commended Revolution Medicines for its pioneering work in advancing KRAS—a target once deemed "undruggable"—and congratulated the company on the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib for metastatic pancreatic cancer. This milestone offers new hope for pancreatic cancer patients and delivers significant clinical value. The Excellence in Client Partnership Award recognizes the trust, dedication, and achievements of both teams over more than three years of collaboration, reflecting Medicilon's confidence in a deeper, long-term partnership.

In-Depth Discussions Explore New Collaboration Opportunities

During the discussions, Dr. Wang outlined Medicilon's growth and its integrated R&D platform spanning target discovery to IND submission. Medicilon's quality system meets international standards and holds NMPA, OECD GLP, FDA GLP, and AAALAC accreditation. Its advanced platforms support ADC/AOC, TPD, RIPTAC, RNAi, and peptide programs. Both parties discussed cross-regional data transfer, project management, future collaboration, and ways to enhance cross-border R&D efficiency.

Laboratory Tour

Subsequently, Drs. Liu and Pota toured Medicilon's R&D laboratories, visiting the chemistry and oligonucleotide labs as well as the API and preclinical research facilities, gaining firsthand insight into Medicilon's R&D infrastructure and quality management system.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"